Flemington et al. also reported that in a subset of KRAS-mutant NSCLC cell lines, the combination of AZD0364 and selumetinib exhibited high synergy, resulting in more profound and sustained suppression of the RAS/MAPK pathway compared to single-agent treatment [40]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.